Summary
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), assessed the risk of "other substances" in food supplements sold in Norway. These risk assessments will provide NFSA with the scientific basis while regulating the addition of "other substances" to food supplements and other foods.
"Other substances" are described in the food supplement directive 2002/46/EC as substances other than vitamins or minerals that have a nutritional and/or physiological effect. It is added mainly to food supplements, but also to other foods. VKM has not in this series of risk assessments of "other substances" evaluated any claimed beneficial effects from these substances, only possible adverse effects.
The present report is a risk assessment of Bacillus coagulans, and it is based on previous risk assessments and articles retrieved from a literature search.
The risk of B. coagulans was assessed for the general population. However, in previous assessments of "probiotics" published by VKM, concerns have been identified for specific groups. Therefore, the risk was assessed for the age group with immature gastro-intestinal microbiota (age group 0-36 months), population with mature gastro-intestinal microbiota (>3 years) and vulnerable groups independent of age. VKM has also assessed the risk of B. coagulans in food supplements independent of the dose and have assessed exposure in general terms.
Other sources of B. coagulans, such as foods, have not been included in the present risk assessment.
VKM concludes that it is unlikely that B. coagulans causes adverse health effects in the general healthy population with mature gastro-intestinal tract. Acquired resistance genes have been detected in this species and the assessment of susceptibility to antibiotics for each single strain is required.
However, no data on long-term adverse effects on infants and young children were identified. As evidence is accruing that the early microbial composition of the neonatal gut is important for the development of the gut microbiota and the immune system of the growing child, it is not possible to exclude that a daily supply of a single particular bacterial strain over a prolonged period of time to an immature gastro-intestinal tract may have long-term, although still unknown, adverse effects on that development. Denne rapporten er en risikovurdering av Bacillus coagulans og er basert på tidligere risikovurderinger og artikler hentet fra litteratursøk.
Risiko for negative helseeffekter av B. coagulans er vurdert med tanke på hele befolkningen.
Mulige uheldige virkninger for bestemte befolkningsgrupper er imidlertid blitt identifisert i tidligere risikovurderinger av probiotika utført av VKM. Risiko er derfor spesielt vurdert for aldersgruppen med umoden tarmflora (aldersgruppe 0-36 måneder), befolkning med moden tarmflora (> 3 år) og sårbare grupper uavhengig av alder. VKM har også vurdert risikoen for negative helseeffekter av B. coagulans i kosttilskudd uavhengig av dose og har vurdert eksponering på generelt grunnlag.
Risikovurderingen inkluderer ikke andre kilder til B. coagulans enn kosttilskudd (som for eksempel mat).
VKM konkluderer med at det er usannsynlig at B. coagulans forårsaker negative helseeffekter i den generelle friske befolkningen med moden tarmflora. Resistensgener er påvist hos noen stammer av B. coagulans og vurdering av antimikrobiell resistens er nødvendig på stammenivå.
Det er imidlertid mangel på data om uønskede langtidsvirkninger for spebarn og små barn (0-36 måneder). Det er økende vitenskapelig dokumentasjon som viser at den mikrobielle sammensetningen i neonatal tarm er viktig for utviklingen av en funksjonell tarmflora og et godt fungerende immunsystem hos det voksende barn. Det kan derfor ikke utelukkes at daglig tilførsel av en enkelt spesifikk bakteriestamme over en lengre tidsperiode til barn med en umoden tarmflora, kan ha langvarige negative effekter på utviklingen av en funksjonell tarmflora. Alternative term to "probiotic":
Currently, there are no approved health claims for probiotics. Applications for health claims on probiotics have been submitted for evaluation to EFSA and no application has received a positive opinion. For this reason, the term 'probiotic', when used on a food label, is considered to be a health claim (http://ec.europa.eu/nuhclaims/) and should not be used and should be replaced by "microorganism".
No claims on probiotics are listed on the EU register as authorised for use. The probiotic claims that have been fully evaluated and rejected are listed as non-authorised on the EU register.
-A probiotic must be alive when administered, -A probiotic must have undergone controlled evaluation to document health benefits in the target host, -A probiotic must be a taxonomically defined microbe or combination of microbes (genus, species and strain level),
-A probiotic must be safe for its intended use.
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Background as provided by the Norwegian Food Safety Authority «Other substances» are substances other than vitamins and minerals, with a nutritional and/or physiological effect on the body. "Other substances" are mainly added to food supplements, but these may also be added to other foods and beverages, such as sports products and energy drinks. Ingestion of these substances in high amounts presents a potential risk for consumers.
While at the EU level, these substances fall under the scope of the European Regulation ( The Norwegian Food Safety Authority (NFSA) has recommended the Norwegian Ministry for Health and Care Services to regulate the addition of "other substances" to food supplements and other foods at a national level. NFSA has suggested using the Danish regulation as a model while establishing a national regulatory framework in Norway. NFSA has further suggested that the establishment of a list of substances with permitted maximal doses should be based on the products and substances found on the Norwegian market.
In preparation for a regulation, NFSA has requested the Norwegian Scientific Committee for Food Safety (VKM) to assess the safety of "other substances" found on the Norwegian market. NFSA, after consultation with the industry, has compiled a list of "other substances" added to food supplements and foods marketed in Norway. NFSA requests VKM to carry out safety assessments for the microorganisms on the list.
Terms of reference as provided by the Norwegian Food Safety Authority
The Norwegian Food Safety Authority (NFSA) has requested the Norwegian Scientific Committee for Food Safety (VKM) to:
Phase 1 Since risk/safety assessments for some of the substances on the list have already been carried out by competent authorities (such as the European Food Safety Authority, Institute of Medicine -USA and Norwegian Scientific Committee for Food Safety), in phase 1 of the assignment, VKM has been requested to:
-make an overview of existing risk/safety assessments for «other substances» enlisted by NFSA, prepared by a competent risk assessment authority.
If assessments for some of these substances exist, then, VKM is requested to:
-describe data on upper limits (UL), guidance limits (GL) or other safe limits established for the substances in these assessments.
Phase 2:
Prepare a guidance document outlining the methodology to be used for the safety assessments of microorganisms.
Phase 3:
Assess the safety of microorganisms in accordance to the guidance document developed in Phase 2.
Safety assessments of microorganisms added to food supplements and other foods shall be carried out for the general population.
The NFSA requests the VKM to describe risks for vulnerable groups such as, infants and babies, pregnant and breast feeding women or those suffering from certain illnesses, in each of these assessments.
Attachment:
The list of microorganisms to be assessed.
Assessment 1 Introduction
This risk assessment addresses the bacterium Bacillus coagulans GBI 30 6086 used as other substance.
VKM has in this series of risk assessments of "other substances" not evaluated documentation of any claimed beneficial effects from these substances.
According to information from the Norwegian Food Safety Authority (NFSA), B. coagulans GBI 30 6086 is an ingredient in food supplements purchased in Norway. Exposure to, B. coagulans GBI 30 6086 from sources other than food supplements, such as food products, is not included in the risk assessment.
The risk of adverse effects from exposure to B. coagulans GBI 30 6086 was assessed for the general population. However, in previous assessments of probiotics published by VKM concerns in specific groups have been identified. Therefore, the risk was estimated for the age group with immature gastro-intestinal microbiota (age group 0-36 months), population with mature gastro-intestinal microbiota (>3 years) and vulnerable groups independent of the age. VKM has also assessed the risk of B. coagulans GBI 30 6086 independent of the dose and have assessed exposure in general terms.
The present report is based on previous risk assessments and articles retrieved from a literature search.
Literature
The present risk assessment is based on EFSA's QPS assessment (EFSA 2008) and articles retrieved from a literature search.
Previous risk assessments
As the recommendation for the QPS status is based on broad criteria, extensive literature searches, and transparent expert judgement, VKM has decided to accept the safety status as given by EFSA in the most up-to-date list including possible qualification criteria . Therefore, the literature search for this assessment has been limited to the reports and articles published in 2015-2016.
Literature search
Following literature search was performed in PUBMED:
Bacillus coagulans GBI 30 6086[Title/Abstract]
The search returned 15 articles.
Other relevant articles, including reports from EFSA (QPS) and FDA (GRAS) are listed in the reference section.
Relevance screening
The titles of all results were scanned by project group, and for those that were of potential relevance, the abstracts were also inspected. The members of the project group performed the relevance screening, independently. Citations were excluded if they did not relate to the terms of reference. The reference lists in selected citations were scrutinized to identify additional articles or reports, not identified by the PubMed searches.
3 Hazard identification and characterisation
Hazard identification
The list of microorganisms attached to the ToR identifies B. coagulans GBI 30 6086 as the microorganism of interest.
Bacillus coagulans GBI 30 6086 belongs to the genus Bacillus. B. coagulans is a sporeforming bacterium that has been or is used as animal feed supplements or plant protection product. There is lack of information regarding origin and deposition of the B. coagulans GBI 30 6086 in a Culture Collection.
The strain genome has been sequenced and published (NCBI, 2016; Orru et al., 2014; Salvetti et al., 2016) .
Hazard characterisation QPS/GRAS
QP S
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A wide variety of microbial species are used in food and feed production. Some have a long history of apparent safe use, while others are less well understood and their use may represent a risk for consumers. Experience has shown that there is a need for a tool for setting priorities within the risk assessment of those microorganisms used in food/feed production referred to EFSA and consequently the subject of a formal assessment of safety.
To meet this need a system was proposed for a pre-market safety assessment of selected groups of microorganisms leading to a "Qualified Presumption of Safety (QPS)". In essence this proposed that a safety assessment of a defined taxonomic group (e.g. genus or group of related species) could be made based on four pillars (establishing identity, body of knowledge, possible pathogenicity and end use). If the taxonomic group did not raise safety concerns or, if safety concerns existed, but could be defined and excluded (the qualification) the grouping could be granted QPS status. Thereafter, any strain of microorganism the identity of which could be unambiguously established and assigned to a QPS group would be freed from the need for further safety assessment other than satisfying any qualifications specified. Microorganisms not considered suitable for QPS would remain subject to a full safety assessment (EFSA 2007) .
The list of the microorganisms have been (and will be) regularly updated by EFSA (EFSA, 2007 (EFSA, , 2008 (EFSA, , 2009 (EFSA, , 2010 (EFSA, , 2012 (EFSA, , 2013 .
GRAS
Any substance that is intentionally added to food is regarded as a food additive and is subject to premarket review and approval by FDA, unless the substance is generally recognized, among qualified experts, as having been adequately shown to be safe under the conditions of its intended use, or unless the use of the substance is otherwise excluded from the definition of a food additive. The use of a food substance may be GRAS either through scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (FDA, 2016) .
The updated list of the microorganisms is published on FDA website http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/
Influence of live microorganisms on the development of gut microbiota
It is now generally recognised that the establishment of the gut microbiota very early in life is a critical stage of development and probably has far-reaching effects on the health of the individual at all ages, including the development of some so-called life-style diseases later in life. Gut colonization begins very early and may in fact even have started before birth (Greenhalgh, Meyer, Aagaard, & Wilmes, 2016) . Immediately after birth a beneficial microbiota develops following transfer of bacteria from the mother during birth, from the birth canal. There follows a further transfer of the mother's own microbiota during breastfeeding from bacteria resident in the breastmilk-producing glands and canals. Human milk contains components that stimulate the growth of these bacteria and therefore further influences and encourages the establishment of a beneficial microbiota. There is also evidence that both oral and faecal microorganisms may be transferred from mother to child at a very early stage (Greenhalgh et al., 2016) .
Colonization of the infant gut mucosa is important in the establishment of the gut mucosal barrier and for maturation of the gut immune system. It is known that infants born by Caesarean section develop a gut microbiota that is more reflective of environmental bacteria. However, several factors can affect this natural progression, including Caesarean delivery, prematurity, use of formula feeds and treatment with antibiotics (Wang, Monaco, & Donovan, 2016) .
The use of antibiotics, both to the neonate and to the mother before parturition, has been shown to change the types and/or the comparative ratios of bacteria in the gut of the neonate. It has been suggested that even a temporary diversion from the establishment of a healthy gut microbiota at this point may cause alterations in the establishment of the adaptive immune system and that this may have many far-reaching effects later in life, such as allergy and autoimmune diseases.
A disturbance in microbiota from what is presently regarded as "normal" is called dysbiosis.
However there is at present no "Gold standard" for the composition of the gut microbiota in neonates and very young children. The human host and its gut microbiota have an important relationship whereby the host recognizes members of the gut microbiota and adjusts the immune response to their presence. Thus the intestinal microbiota of the neonate guides the development of the immune system and a tolerance to the host commensal bacteria. It has been suggested that dysbiosis may be the cause of many conditions, including necrotizing enterocolitis, inflammatory bowel disease, irritable bowel syndrome, atopic and allergic disease and metabolic diseases including obesity and diabetes 1. However, dysbiosis may influence these diseases in different ways -by affecting the immune system or by a direct result of the changed microbiota (Wang et al., 2016) . Dysbiosis at an early age can predispose to obesity at any age in life. This may be due to the establishment of a different balance of microorganisms in the gut microbiota which are able to extract energy from multiple sources and thus predispose the host to obesity.
Studies of the role of the neonates GIT microbiota indicate a diversity of microorganisms that include, but not exclusively, such bacteria as lactobacilli and bifidobacteria. Present opinion suggests that this diversity in itself is an important factor. The inclusion of large numbers of one particular strain of probiotic bacteria in the diet of a neonate can therefore be questioned. Indeed, Berstad et al (2016) voiced concern that ingestion of probiotics could negatively affect the resident commensal flora and leave an empty ecological niche following cessation of treatment. Some probiotic strains have been shown to have a number of effects on neonate conditions that can be attributed to the gut microbiota. However, long-term studies of the effects of consumption of probiotic cultures have not been done and therefore it has not been possible to evaluate the long-term effects of manipulating the gut microbiota in neonates and very young children. Similarly, it has not been possible to evaluate the safety of the establishment of a less diverse microbiota as a consequence of feeding probiotics to very young children.
Antimicrobial resistance properties of B. coagulans GBI 30 6086
As a part of genome sequencing, the antimicrobial properties of B. coagulans were analysed.
Results obtained showed that strain GBI-30 6086 was resistant only to kanamycin and streptomycin, MIC values being higher than 1500 mg/L (EFSA, 2007; Salvetti et al., 2016) .
When the Comprehensive Antibiotic Resistance Database (CARD) was used to search the genome of B. coagulans GBI-30, 6086 for AR-related genes (E < 1e-2, coverage > 70 % and similarity > 30 %) the analysis led to the identification of 109 putative AR genes. Most of which included transporters (57), genes modulating the antibiotic efflux (9), genes associated with resistance to daptomycin (6), polymyxin (1), streptothricin (1), penicillin (5), vancomycin (13), elfamycin (1), rifampin (2), sulphonamide (1), macrolides (as erythromycin, streptogramin and chloramphenicol) (2), fluoroquinolone (2), aminocoumarin (2) trimethoprim (1), other genes related to a non-specified antibiotic resistance (4) and aminoglycosides (2). The two identified aminoglycoside resistance genes, IE89_07115 and IE89_03650, encoded for the ribosomal protein S12 of subunit 30S and an aminoglycoside 3-Nacetyltransferase, respectively. However, since the determinants for this resistance appear to be not easily transferrable to other bacteria and no other AR phenotypes were observed in GBI-30, 6086, it can be assumed that genes retrieved by in silico analysis were not functional or not expressed at a sufficient level or only partially similar to known resistance genes, but do not represent a harmful trait of this bacterium (Salvetti et al., 2016) .
Safety concerns
For decades, strains belonging to several species of Bacillus have been deliberately introduced into the food chain either as plant protection products or as an animal feed supplement. The knowledge gained from this use suggests that, for some species at least, their safety could be assured by the "Qualified Presumption of Safety" (QPS). Several strains belonging to the species B. coagulans have been used as probiotics, animal feed supplements or in aquaculture (EFSA, 2007; Hong, Duc, & Cutting, 2005) . As no safety concerns have been identified and this species has generally been considered to be nonpathogenic no safety concerns are envisaged (EFSA, 2007) . Since there are no safety concerns the only qualification required is the assessment of susceptibility to antibiotics for each single strain (EFSA, 2007) .
The American Food and Drug Administration (FDA) classified it as GRAS (FDA, 2011) .
Possible infectivity of a B. coagulans GBI 30 6086 in vulnerable groups
Previously published assessments have identified vulnerable groups as; pregnant women, children, elderly people, immunocompromised and critically ill patients (VKM, 2014 (VKM, , 2016 .
Previously published assessments and literature search conducted for this assessment have not identified safety concerns for these vulnerable groups.
However, no studies on long-term effects on infants and young children were identified in the literature search. As evidence is accruing that the early microbial composition of the neonatal gut is important for the development of the gut microbiota and the immune system of the growing child, it is not possible to exclude that a daily supply of a single particular bacterial strain over a prolonged period of time to an immature gastro-intestinal tract may have long-term, although still unknown, adverse effects on that development.
Exposure assessment
As this assessment is concerned with general safety of the B. coagulans GBI 30 6086 and is not related to a specific product or dose, the exposure assessment is given in general terms.
The dose ingested in the portion of the product usually recommended for daily consumption contains log 9 of at least one strain among those present in the product. The use of different number of microorganism may be allowed when its rationale has been demonstrated by significant scientific studies. The number of cells must be specified on the product label, and moreover, this number has to be guaranteed until the end of the product shelf-life, at the specified storage conditions, with uncertainty of 0.5 log units. It is emphasized that the analytical method of quantification of living bacterial cells may differ from species to species (Ministero, 2013) .
Regarding consumption by infants, Fernandez et al. (2003) extrapolated from the results of several authors that an infant would consume between log 5 and log 7 bacteria daily along with the consumption of 800 ml breast milk. As a comparison, a 100 g serving of commercial probiotic yoghurt would contain approximately log 9-10 CFU. Thus the amount of cells consumed in a serving of yoghurt would be considerably higher than natural milk levels, in fact up to 10 000 x greater (difference between log 5 and log 9).
Risk characterisation
The safety aspects of B. coagulans GBI 30 6086 give no reason for concern and it has been granted QPS status by EFSA, provided that the lack of acquired antibiotic resistance is demonstrated and GRAS status by FDA. However, no data on long-term adverse effects on infants and young children were identified. As evidence is accruing that the early microbial composition of the neonatal gut is important for the development of the gut microbiota and the immune system of the growing child, it is not possible to exclude that a daily supply of a single particular bacterial strain over a prolonged period of time to an immature gastrointestinal tract may have long-term, although still unknown, adverse effects on that development.
The safety aspects of B. coagulans GBI 30 6086 assessed in this risk assessment for vulnerable groups other than the one with immature gastrointestinal tract give no reason for concern.
6 Uncertainties
According to EFSA's guidance regarding uncertainties: assessments must state clearly and unambiguously the uncertainties that have been identified and their impact on the overall assessment outcome.
Consumption of microorganism B. coagulans GBI 30 6086 in a "normal" dose is considered safe in an adult (> 3 years) "normal" population. In this assessment, some uncertainties have been identified. Many of these uncertainties may overlap with the data gaps (Section 8).
The uncertainties identified are as follows:
• Long-term effects on infants and young children • Consumption by vulnerable groups other than the group with immature gastro-intestinal tract 7 Conclusions with answers to the terms of reference VKM concludes that it is unlikely that B. coagulans GBI 30 6086 causes adverse health effects in the population with mature gastro-intestinal tract (>3 years). However, it is not possible to exclude that a daily supply of a single particular bacterial strain over a prolonged period of time to an immature gastro-intestinal tract may have long-term, although still unknown, adverse effects on that development.
Data gaps
• Studies on adverse effects in children and vulnerable groups are lacking.
